PI
ADCT icon

PEAK6 Investments’s ADC Therapeutics ADCT Stock Holding History

PEAK6 Investments’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-31,912
Closed -$777K – 5051
2021
Q2 		$777K Hold
31,912
– – ﹤0.01% 2830
2021
Q1 		$779K Buy
31,912
+10
+0% +$290 ﹤0.01% 2795
2020
Q4 		$1.02M Sell
31,902
-201,210
-86% -$6.59M ﹤0.01% 2462
2020
Q3 		$7.69M Hold
233,112
– – 0.02% 717
2020
Q2 		$10.9M Buy
+233,112
New +$8.85M 0.04% 451

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

PEAK6 Investments's ADCT Position: Q3 2021 in Review

PEAK6 Investments sold out of ADC Therapeutics (ADCT) in Q3 2021, closing a stake of 31,912 shares — an estimated $777K sold.

PEAK6 Investments first reported a position in ADCT in Q2 2020 and held it in 5 quarters. The position peaked at $10.9M in Q2 2020. 53 funds tracked by Wall St. Rank hold ADCT as of Q3 2021.

  • PEAK6 Investments reported no remaining ADC Therapeutics position as of Q3 2021 after selling out during the quarter.
  • PEAK6 Investments sold 31,912 ADC Therapeutics shares in Q3 2021, an estimated $777K.
  • PEAK6 Investments first reported a position in ADC Therapeutics in Q2 2020 and held it in 5 quarters.
  • PEAK6 Investments's ADC Therapeutics position peaked at $10.9M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2021.

Based on PEAK6 Investments's 13F filing for Q3 2021, filed 12 Nov 2021.